Suppr超能文献

FAM83D 基因在肝细胞癌中的免疫意义。

Immune implication of FAM83D gene in hepatocellular carcinoma.

机构信息

Department of General Surgery and Centre Laboratory, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

Department of General Surgery, Hefei City First People's Hospital, Hefei, China.

出版信息

Bioengineered. 2021 Dec;12(1):3578-3592. doi: 10.1080/21655979.2021.1950260.

Abstract

FAM83D has been demonstrated to contribute to tumorigenesis. However, its immune effects in hepatocellular carcinoma (HCC) have not been reported. This study aimed to identify the immune role of FAM83D in HCC. FAM83D was over-expressed in HCC and contributed to poor prognosis according to the results of data analysis based on The Cancer Genome Atlas (TCGA). Afterward, the levels of immune cells infiltration were found to be correlated with the expression level of FAM83D in HCC. Through TISIDB and cBioPortal network tools, a total of 82 FAM83D-associated genes were screened out, including 12 immunoinhibitors, 20 immunostimulators and 50 tightly co-expressed genes. TCGA cohort was divided into train set and test set on the basis of the proportion of 7:3. According to FAM83D-associated immunomodulators, a four gene predicted model was established using train set via the Cox regression analysis. Survival analysis demonstrated that the overall survival (OS) of high-risk HCC patients was poor compared with the patients in low-risk group. The reliability and predicted power of the risk-score model were identified by a receiver operating characteristic (ROC) curve. A risk-score based nomogram as well as a calibration curve, which were created could be used to anticipate patient's 1-year, 3-year and 5-year survival probabilities. The test set was used to validate these results. Our findings showed that the FAM83D gene was related with HCC immunity. The immune marker chosen could be a promising biomarker for HCC prognosis.

摘要

FAM83D 已被证明有助于肿瘤发生。然而,其在肝细胞癌(HCC)中的免疫作用尚未报道。本研究旨在确定 FAM83D 在 HCC 中的免疫作用。根据基于癌症基因组图谱(TCGA)的数据分析结果,FAM83D 在 HCC 中过表达,并导致预后不良。此后,发现免疫细胞浸润水平与 HCC 中 FAM83D 的表达水平相关。通过 TISIDB 和 cBioPortal 网络工具,共筛选出 82 个 FAM83D 相关基因,包括 12 个免疫抑制剂、20 个免疫刺激剂和 50 个紧密共表达基因。根据 FAM83D 相关免疫调节剂,将 TCGA 队列按 7:3 的比例分为训练集和测试集。使用训练集通过 Cox 回归分析建立了基于 FAM83D 相关免疫调节剂的四个基因预测模型。生存分析表明,高危 HCC 患者的总生存期(OS)明显不如低危组患者。通过受试者工作特征(ROC)曲线确定了风险评分模型的可靠性和预测能力。基于风险评分的列线图和校准曲线可以用于预测患者 1 年、3 年和 5 年的生存率。使用测试集验证了这些结果。我们的研究结果表明,FAM83D 基因与 HCC 免疫有关。选择的免疫标志物可能是 HCC 预后的有前途的生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a47/8806426/f543623aa245/KBIE_A_1950260_UF0001_B.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验